Xalkori crizotinib: Phase I data

Data from 25 evaluable NSCLC patients who previously received 1 or 2 prior chemotherapy regimens in the Phase I portion of an open-label, U.S. Phase I/II trial showed that twice-daily 150 and 200 mg Xalkori in combination with Tarceva erlotinib produced 1 partial response with a duration of 61 weeks, plus 9 cases of stable disease (SD) with a duration of 7-54 weeks. The combination was well tolerated with diarrhea, rash and fatigue reported as the most common treatment-related adverse events. The MTD was twice-daily 150 mg Xalkori plus once-daily 100 mg Tarceva. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...